First Quarter 2026 Earnings Presentation March 10, 2026 Forward Looking Statements This press release contains both historical and forward-looking statements about ABM Industries Incorporated ("ABM") and its subsidiaries (collectively referred to as "ABM," "we," "us," "our," or the "Company"). We make forward-looking statements related to future expectations, estimates and projections that are uncertain, and often contain words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "int ...

Q4'25 Earnings Presentation March 2026 None of the information contained in this presentation has been audited by any independent auditor. This presentation is prepared as a convenience for securities analysts and investors and may be useful as a reference tool. Riley Permian may elect to modify the format or discontinue publication at any time, without notice to securities analysts or investors. Forward-Looking Statements Use of non-GAAP Financial Information This presentation contains projections and othe ...

Stevanato Group Q4 and FY 2025 Financial Results March 4, 2026 Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. ("we", "our", "us", "Stevanato Group" or the "Company") and which involve known and unknown risks, uncertainties and assumptions because they relate to events and depend on circumstances that will occur in ...

Brunswick Corporation David Foulkes, Chairman and CEO RAYMOND JAMES CONFERENCE – ORLANDO, FL MARCH 3, 2026 ©2026 BR UN SWICK CO. CON FID ENTIAL AN D ALL R IGHTS R ESERVED . Forward-Looking Statements Certain statements in this presentation are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and projections about Brunswick's business and by their nature address matters that are, to differen ...

Core Insights - Dave Inc. reported a significant financial performance for Q4 and FY 2025, with Q4 revenue increasing by 62% to $163.7 million and FY 2025 revenue rising by 60% to $554.2 million [1] - The company achieved a Q4 net income growth of 292% to $66.0 million and a FY 2025 net income increase of 238% to $195.9 million [1] - Adjusted EBITDA for Q4 rose by 118% to $72.9 million, while FY 2025 adjusted EBITDA increased by 162% to $226.7 million [1] - Dave established a 2026 outlook projecting revenue growth of 25% to 28% and expanding adjusted EBITDA margins [1] Financial Highlights - Q4 GAAP operating revenues were $163.7 million, reflecting a 62% year-over-year increase [1] - FY 2025 GAAP operating revenues totaled $554.2 million, a 60% increase compared to FY 2024 [1] - Non-GAAP gross profit for Q4 was $121.9 million, with a gross profit margin of 74% [1] - FY 2025 non-GAAP gross profit reached $401.5 million, with a gross profit margin of 72% [1] Operational Metrics - The number of monthly transacting members (MTMs) increased by 19% year-over-year to 2.93 million [1] - New member acquisition in Q4 was 867,000, with a customer acquisition cost of $20 [1] - Average 28-day past due rate improved by 12% quarter-over-quarter to 1.89% [1] - ExtraCash originations grew by 50% year-over-year to $2.2 billion [1] Liquidity and Capital Allocation - As of December 31, 2025, the company had $123.2 million in cash and cash equivalents, up from $93.6 million as of September 30, 2025 [1] - The company increased its share repurchase authorization from $125 million to $300 million [1] - The CFO highlighted strong conversion of adjusted EBITDA into free cash flow, providing flexibility for capital allocation priorities [2] 2026 Financial Guidance - For FY 2026, Dave projects GAAP operating revenues between $690 million and $710 million, representing a year-over-year growth of 25% to 28% [1] - Adjusted EBITDA for FY 2026 is expected to be between $290 million and $305 million [1] - The company anticipates adjusted EPS (diluted) to be in the range of $14.00 to $15.00 [1]

Core Insights - Zymeworks Inc. has redefined its strategy focusing on long-term value creation through disciplined capital allocation and a growing royalty portfolio, aiming for sustainable shareholder returns [2][3] - The company reported a total revenue of $106.0 million for 2025, a 39% increase from 2024, and reduced its net loss by 34% to $81.1 million [20][24] - A $250.0 million royalty-backed note financing arrangement with Royalty Pharma was established to support share repurchases and strategic acquisitions [3][5] Recent Developments - Zymeworks entered into a $250.0 million royalty-backed note financing with Royalty Pharma, allowing for greater near-term cash flow preservation [3] - The company expects to complete a supplemental Biologics License Application for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma by Q1 2026, with a potential launch in the second half of 2026 [5][8] - Zymeworks has received $53.0 million in milestone payments for Ziihera and is eligible for up to $440.0 million in additional milestone payments related to regulatory approvals in various regions [11][12] Financial Performance - Total revenue for 2025 was $106.0 million, driven by significant clinical and regulatory milestones, compared to $76.3 million in 2024 [20] - Research and development expenses for 2025 were $137.0 million, an increase from $134.6 million in 2024, primarily due to higher costs associated with clinical studies [21] - The company reported a net loss of $81.1 million for 2025, down from a net loss of $122.7 million in 2024 [24] Share Repurchase Program - The Board of Directors authorized a new share repurchase program allowing for the repurchase of up to $125.0 million in common stock [16] - As of March 2, 2026, approximately $62.5 million has been utilized to repurchase shares at an average price of $24.22 per share [17] Research and Development Focus - Zymeworks plans to continue Phase 1 clinical studies for ZW191 and ZW251 in 2026, with Investigational New Drug applications for ZW209 and ZW1528 on track for submission [6] - The company anticipates one planned IND filing per annum from its multispecific antibody portfolio starting in 2028 [6] Liquidity and Financial Outlook - As of December 31, 2025, Zymeworks had $270.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations beyond 2028 [25] - The company expects adjusted gross operating expenses to be approximately 20% lower in 2026 compared to 2025, reflecting a disciplined investment approach [18]

Fourth Quarter and Full Year 2025 Earnings Presentation costs; and • fluctuations in the amount and frequency of repurchases of our common stock. February 27, 2026 1 Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial per ...

Thursday, February 26, 2026 Q4 & Full-Year 2025 Earnings Call Presentation Safe Harbor for Forward-Looking Statements Safe Harbor Statement Some of the statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable law. Such forward-looking statements may be identified by the use of words, such as "project," "believe," "expect," "anticipate," "intend," "plan," "estimate," "continue," "potential," "forecast" or ...

Core Insights - ARRAY Technologies, Inc. achieved a 40% full-year revenue growth, with a record order book of $2.2 billion, and is guiding for 2026 revenue between $1.4 billion and $1.5 billion [1][2][5] Financial Highlights - For Q4 2025, revenue was $226 million, and for the full year 2025, revenue reached $1,284.1 million, reflecting a significant increase from $915.8 million in 2024 [1][27] - Gross margin for Q4 2025 was 8.6%, while the full-year gross margin was 23.2% [1][27] - Adjusted EBITDA for Q4 2025 was $11.2 million, with a full-year adjusted EBITDA of $187.6 million [1][27] - The net loss to common shareholders for Q4 2025 was $161.2 million, compared to a loss of $112 million for the full year [1][27] Business Developments - The company reported a 35% volume growth for the full year 2025, surpassing broader industry trends, indicating strong demand for its differentiated technology [2] - ARRAY is focusing on international expansion of its DuraTrack technology and plans to launch multiple new products in 2026, including an integrated tracker and foundation solution [2][3] - The company has made strategic investments in enhancing its commercial organization and customer engagement, which contributed to its strong performance [2] Future Guidance - For 2026, ARRAY expects approximately $200 million in revenue for Q1, with a projected adjusted EBITDA range of $200 million to $230 million [3][5] - The company anticipates a revenue split of 40% in the first half and 60% in the second half of 2026, influenced by regulatory uncertainties [3]

Core Insights - UFP Technologies, Inc. reported a net income of $68.3 million for 2025, a 15.8% increase from $59.0 million in 2024, with adjusted net income growing 12.7% to $76.1 million [1][3] - Net sales for 2025 reached $602.8 million, representing a 19.5% increase from $504.4 million in 2024 [1][4] - The company experienced a 23.2% increase in medical sales, while non-medical sales decreased by 11.5% [3][4] Financial Performance - For Q4 2025, sales increased by 3.4% to $148.9 million compared to $144.1 million in Q4 2024 [4] - Year-to-date sales for 2025 increased by 19.5% to $602.8 million from $504.4 million in 2024 [4] - Gross margin for Q4 2025 was 28.2%, down from 29.2% in Q4 2024, while the full-year gross margin decreased to 28.3% from 29.1% [4][5] Operating Income and Expenses - Operating income for the year increased by 14.1% to $92.3 million from $80.9 million in 2024 [9] - Selling, general and administrative expenses (SG&A) rose by 24.5% to $77.4 million for the year, with SG&A as a percentage of sales increasing to 12.8% from 12.3% [5][9] Strategic Initiatives - The company expanded its operations in the Dominican Republic, extending contracts and launching new programs [3] - Four acquisitions in 2024 and three in 2025 are progressing well, with integrations either underway or complete [3] Market Segmentation - Medical market sales for 2025 were $555.3 million, a 23.2% increase, while non-medical sales decreased to $47.5 million [4][9] - Organic sales growth for the year was approximately 1.5%, with Q4 organic sales remaining flat compared to the same period in 2024 [4][18]